Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

14 May 2020

Abstract excerpt

Despite the improvement in clinical outcome with 13-cis-retinoic acid (13-cisRA) + anti-GD2 antibody + cytokine immunotherapy given in first response ~40% of high-risk neuroblastoma patients die of recurrent disease. MYCN genomic amplification is a biomarker of aggressive tumors in the childhood cancer neuroblastoma. MYCN expression is downregulated by 13-cisRA, a differentiating agent that is a component of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments
Share to Zebrafish Biomedical Research Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32409685
DOI: 10.1038/s41419-020-2563-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastomaPMID 32409685Read ↗

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaSemantic proximity Read ↗

Neuroblastoma and MYCN.Semantic proximity Read ↗

High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastomaSemantic proximity Read ↗

Functional interplay between <scp>MYCN</scp>,<scp> NCYM</scp>, and <scp>OCT</scp>4 promotes aggressiveness of human neuroblastomasSemantic proximity Read ↗

METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastomaSemantic proximity Read ↗

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable OutcomeSemantic proximity Read ↗

Neuroblastoma treatment in the post-genomic eraSemantic proximity Read ↗

MYCN inhibits TrkC-mediated differentiation in neuroblastoma cells via disruption of the PKA signalling pathwaySemantic proximity Read ↗

Palbociclib releases the latent differentiation capacity of neuroblastoma cellsSemantic proximity Read ↗

Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesisSemantic proximity Read ↗

Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.Semantic proximity Read ↗

Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.